All In Biotech

Drug Trial Radar · NCT01014208

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant (ASCT) in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Last checked: Nov 20, 2026Latest source record: Aug 7, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 447 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

447

Actual

Start

Mar 2010

Primary completion

Feb 2014

Study completion Nov 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to compare the efficacy and safety of ofatumumab in addition to salvage chemotherapy versus rituximab in addition to salvage chemotherapy in CD20 positive DLBCL subjects relapsing, or with persistent disease, after first-line treatment with rituximab combined with an anthracycline-based chemotherapy regimen and be eligible for ASCT.

Conditions

  • Lymphoma, Large-Cell, Diffuse

Interventions

  • OFATUMUMAB + DHAPDrug

    3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.

  • RITUXIMAB + DHAPDrug

    3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival as Assessed by Independent ReviewersTime frame: From randomization until the date of stable disease after two cycles of salvage chemotherapy, progression, or death (assessed for up to 5 years)

Locations

173 sites in 26 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Chicago, Illinois

  • GSK Investigational Site

    Westwood, Kansas

  • GSK Investigational Site

    Jackson, Mississippi

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Syracuse, New York

  • GSK Investigational Site

    Chaple Hill, North Carolina

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Providence, Rhode Island

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Seattle, Washington

  • GSK Investigational Site

    Capital Federal, Buenos Aires, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • GSK Investigational Site

    La Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Graz, Austria

  • GSK Investigational Site

    Innsbruck, Austria

  • GSK Investigational Site

    Linz, Austria

  • GSK Investigational Site

    Linz, Austria

  • GSK Investigational Site

    Salzburg, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Bruges, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Ghent, Belgium

  • GSK Investigational Site

    Hasselt, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Yvoir, Belgium

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Chengdu, China

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.